Life Sciences
Also, Syntekabio has launched its cloud service platform for AI drug discovery.
Transcarent announced it would expand into the pharmacy benefit space in September.
The multinational pharma company will now be able to access Tempus' de-identified patient data.
The company also announced a partnership with pharma giant Biogen that allows providers to submit enrollment forms for its multiple sclerosis drug Vumerity through the new platform.
Dr. Oliver Bleck, area head of Europe South at Roche, describes the pharma giant's work in personalized medicine.
The collaboration aims to lower the cost of prescription drugs for Capital Blue Cross members.
The alliance will expand Sanofi's trek into tech-based drug discovery and development platforms.
Kaleidoscope, Surge, Optellum, Cionic and Arcascope also announce funding rounds.
Mati Gil, CEO of AION Labs, describes how its new startup OMEC.AI came to fruition and what it aims to accomplish for drug discovery and development.
Device Connect for Fitbit aims to help healthcare and life science organizations use and analyze data from Fitbit's health-tracking wearables.